MX2024009163A - Sintesis de un inhibidor de kif18a. - Google Patents
Sintesis de un inhibidor de kif18a.Info
- Publication number
- MX2024009163A MX2024009163A MX2024009163A MX2024009163A MX2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A MX 2024009163 A MX2024009163 A MX 2024009163A
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- kif18a
- inhibitor
- synthesis
- salt
- Prior art date
Links
- 101001091231 Homo sapiens Kinesin-like protein KIF18A Proteins 0.000 title abstract 2
- 229940126262 KIF18A Drugs 0.000 title abstract 2
- 102100034895 Kinesin-like protein KIF18A Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 9
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Silver Salt Photography Or Processing Solution Therefor (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263303470P | 2022-01-26 | 2022-01-26 | |
| PCT/US2023/011636 WO2023146973A1 (en) | 2022-01-26 | 2023-01-26 | Synthesis of a kif18a inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024009163A true MX2024009163A (es) | 2024-08-09 |
Family
ID=85328813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024009163A MX2024009163A (es) | 2022-01-26 | 2023-01-26 | Sintesis de un inhibidor de kif18a. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250129050A1 (https=) |
| EP (1) | EP4469437A1 (https=) |
| JP (1) | JP2025505892A (https=) |
| KR (1) | KR20240144140A (https=) |
| CN (1) | CN118922406A (https=) |
| AR (1) | AR128353A1 (https=) |
| AU (1) | AU2023211589A1 (https=) |
| CA (1) | CA3248925A1 (https=) |
| IL (1) | IL314221A (https=) |
| MX (1) | MX2024009163A (https=) |
| TW (1) | TW202342451A (https=) |
| WO (1) | WO2023146973A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| TW202416973A (zh) | 2022-08-18 | 2024-05-01 | 美商雅客森醫療公司 | Kif18a抑制劑及其用途 |
| CN115925589A (zh) * | 2022-12-26 | 2023-04-07 | 诚达药业股份有限公司 | 一种脂肪族亚磺酸钙盐及其制备方法 |
| WO2025036479A1 (zh) * | 2023-08-16 | 2025-02-20 | 上海湃隆生物科技有限公司 | 驱动蛋白kif18a抑制剂及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54543A (fr) * | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| MX2022012992A (es) * | 2020-04-14 | 2022-11-08 | Amgen Inc | Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas. |
-
2023
- 2023-01-26 IL IL314221A patent/IL314221A/en unknown
- 2023-01-26 WO PCT/US2023/011636 patent/WO2023146973A1/en not_active Ceased
- 2023-01-26 CA CA3248925A patent/CA3248925A1/en active Pending
- 2023-01-26 US US18/832,887 patent/US20250129050A1/en active Pending
- 2023-01-26 EP EP23706921.6A patent/EP4469437A1/en active Pending
- 2023-01-26 AU AU2023211589A patent/AU2023211589A1/en active Pending
- 2023-01-26 CN CN202380018655.9A patent/CN118922406A/zh active Pending
- 2023-01-26 JP JP2024543870A patent/JP2025505892A/ja active Pending
- 2023-01-26 KR KR1020247024721A patent/KR20240144140A/ko active Pending
- 2023-01-26 MX MX2024009163A patent/MX2024009163A/es unknown
- 2023-01-26 AR ARP230100178A patent/AR128353A1/es unknown
- 2023-01-30 TW TW112103047A patent/TW202342451A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118922406A (zh) | 2024-11-08 |
| CA3248925A1 (en) | 2023-08-03 |
| JP2025505892A (ja) | 2025-03-03 |
| TW202342451A (zh) | 2023-11-01 |
| AR128353A1 (es) | 2024-04-24 |
| EP4469437A1 (en) | 2024-12-04 |
| WO2023146973A1 (en) | 2023-08-03 |
| IL314221A (en) | 2024-09-01 |
| KR20240144140A (ko) | 2024-10-02 |
| US20250129050A1 (en) | 2025-04-24 |
| AU2023211589A1 (en) | 2024-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024009163A (es) | Sintesis de un inhibidor de kif18a. | |
| AR117101A1 (es) | Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras | |
| PE20231938A1 (es) | Inhibidores de cdk y metodos de uso de estos | |
| CL2024003354A1 (es) | Compuesto cíclico que tiene acción inhibitoria selectiva sobre kras por encima de hras y nras | |
| AR121483A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| CO6400227A2 (es) | Análogos de nucleosidos | |
| PE20050012A1 (es) | Compuestos de benzopirano como inhibidores de la ciclooxigenasa-2 | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| CY1111481T1 (el) | Υποκατεστημενα αρυλοκυκλοπροπυλακεταμιδια ως ενεργοποιητες γλυκοκινασης | |
| CY1118862T1 (el) | Νεα δικυκλικη ετεροκυκλικη ενωση | |
| CY1114689T1 (el) | C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης | |
| MXPA04002993A (es) | Compuestos de espiro-hidantoina utiles como agentes anti-inflamatorios. | |
| MX2024012348A (es) | Forma cristalina de lanifibranor | |
| ES2052452B1 (es) | Procedimiento de preparacion de inhibidores duales de no-sintasa y ciclooxigenasa. | |
| AR124694A1 (es) | Hidrato cristalino de sal de sodio de topramezona novedoso y método de preparación del mismo | |
| UA108760C2 (uk) | Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби | |
| CO2024013702A2 (es) | Derivados de pirido-[3,4-d]piridazina amina útiles como derivados de nlrp3 | |
| CO2021014210A2 (es) | Compuestos de pirrol | |
| EA201290872A1 (ru) | Способ получения бензоксаборолов | |
| CL2021000171A1 (es) | Procedimiento y productos intermedios para la preparación de bilastina | |
| PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
| PA8650401A1 (es) | Sintesis asimetrica de dihidrobenzofuranos sustituidos | |
| PY2269931A (es) | Un proceso para la preparación de piroxasulfona | |
| EA021733B1 (ru) | Ключевые промежуточные соединения для синтеза розувастатина или его фармацевтически приемлемых солей | |
| ES2557477T3 (es) | Nuevos compuestos peptídicos cíclicos |